AU2012351843B2 - Method of treatment employing therapeutic T cell product from mobilised donors - Google Patents
Method of treatment employing therapeutic T cell product from mobilised donors Download PDFInfo
- Publication number
- AU2012351843B2 AU2012351843B2 AU2012351843A AU2012351843A AU2012351843B2 AU 2012351843 B2 AU2012351843 B2 AU 2012351843B2 AU 2012351843 A AU2012351843 A AU 2012351843A AU 2012351843 A AU2012351843 A AU 2012351843A AU 2012351843 B2 AU2012351843 B2 AU 2012351843B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- mobilised
- cell
- antigen
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 157
- 238000000034 method Methods 0.000 title claims abstract description 65
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 28
- 238000011282 treatment Methods 0.000 title description 16
- 239000000427 antigen Substances 0.000 claims abstract description 68
- 102000036639 antigens Human genes 0.000 claims abstract description 68
- 108091007433 antigens Proteins 0.000 claims abstract description 68
- 239000008280 blood Substances 0.000 claims abstract description 53
- 210000004369 blood Anatomy 0.000 claims abstract description 49
- 238000002617 apheresis Methods 0.000 claims abstract description 33
- 239000003550 marker Substances 0.000 claims abstract description 28
- 230000004913 activation Effects 0.000 claims abstract description 20
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 13
- 230000003612 virological effect Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 159
- 102100032937 CD40 ligand Human genes 0.000 claims description 49
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 49
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 230000000638 stimulation Effects 0.000 claims description 23
- 241000700605 Viruses Species 0.000 claims description 20
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 12
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 12
- 108091008874 T cell receptors Proteins 0.000 claims description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 10
- 230000000735 allogeneic effect Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000011476 stem cell transplantation Methods 0.000 claims description 10
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 9
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 9
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 9
- 241000701022 Cytomegalovirus Species 0.000 claims description 8
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 7
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 7
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 239000002458 cell surface marker Substances 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 241000829111 Human polyomavirus 1 Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 80
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 56
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 55
- 239000000047 product Substances 0.000 description 45
- 239000000523 sample Substances 0.000 description 37
- 108091008048 CMVpp65 Proteins 0.000 description 33
- 102000004127 Cytokines Human genes 0.000 description 28
- 108090000695 Cytokines Proteins 0.000 description 28
- 230000008569 process Effects 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108010002350 Interleukin-2 Proteins 0.000 description 17
- 102000000588 Interleukin-2 Human genes 0.000 description 17
- 108090000978 Interleukin-4 Proteins 0.000 description 15
- 102000004388 Interleukin-4 Human genes 0.000 description 15
- 108010002586 Interleukin-7 Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 230000028327 secretion Effects 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000007858 starting material Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000003248 secreting effect Effects 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 10
- 101150013553 CD40 gene Proteins 0.000 description 9
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 8
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 108090000172 Interleukin-15 Proteins 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 238000011287 therapeutic dose Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000008070 Interferon-gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 229960003130 interferon gamma Drugs 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- -1 IFN-y Proteins 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 102000000743 Interleukin-5 Human genes 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 101710183015 Trans-activating transcriptional regulatory protein Proteins 0.000 description 3
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 3
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 3
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000006058 immune tolerance Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 101000878581 Aplysia californica Feeding circuit activating peptides Proteins 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- QHNORJFCVHUPNH-UHFFFAOYSA-L To-Pro-3 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 QHNORJFCVHUPNH-UHFFFAOYSA-L 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000004046 hyporesponsiveness Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000024717 negative regulation of secretion Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 102000036213 phospholipid binding proteins Human genes 0.000 description 1
- 108091011000 phospholipid binding proteins Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/24—Gas permeable parts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/18011—Nimaviridae
- C12N2710/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Sustainable Development (AREA)
- Clinical Laboratory Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Developmental Biology & Embryology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1121308.9 | 2011-12-12 | ||
| GBGB1121308.9A GB201121308D0 (en) | 2011-12-12 | 2011-12-12 | Process |
| PCT/GB2012/053114 WO2013088148A2 (en) | 2011-12-12 | 2012-12-12 | Method of treatment employing therapeutic t cell product from mobilised donors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012351843A1 AU2012351843A1 (en) | 2014-07-31 |
| AU2012351843B2 true AU2012351843B2 (en) | 2016-05-12 |
Family
ID=45560301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012351842A Active AU2012351842B2 (en) | 2011-12-12 | 2012-12-12 | Process for T cell expansion |
| AU2012351843A Ceased AU2012351843B2 (en) | 2011-12-12 | 2012-12-12 | Method of treatment employing therapeutic T cell product from mobilised donors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012351842A Active AU2012351842B2 (en) | 2011-12-12 | 2012-12-12 | Process for T cell expansion |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US20140341951A1 (https=) |
| EP (2) | EP2791323A2 (https=) |
| JP (6) | JP2015505852A (https=) |
| AU (2) | AU2012351842B2 (https=) |
| ES (1) | ES2626492T5 (https=) |
| GB (1) | GB201121308D0 (https=) |
| HK (1) | HK1203219A1 (https=) |
| WO (2) | WO2013088147A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102625832A (zh) | 2009-08-24 | 2012-08-01 | 贝勒医学院 | 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系 |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| ES2748652T3 (es) | 2012-02-09 | 2020-03-17 | Baylor College Medicine | Mezclas pep para generar CTL multivíricos con amplia especificidad |
| EP2859093A4 (en) * | 2012-06-11 | 2016-08-17 | Wolf Wilson Mfg Corp | IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES |
| WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| GB201509202D0 (en) | 2015-05-28 | 2015-07-15 | Ge Healthcare Bio Sciences Ab | Semi-static cell culture |
| WO2016209816A1 (en) * | 2015-06-26 | 2016-12-29 | Memorial Sloan Kettering Cancer Center | Methods of treating cmv retinitis by t cell therapy |
| EP3350600A4 (en) | 2015-09-18 | 2019-04-17 | Baylor College of Medicine | DISTINCTION OF AN IMMUNOGENIC ANTIGEN OF A PATHOGEN AND CORRELATION WITH CLINICAL EFFECTIVENESS |
| EP3365453A2 (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Methods, kits, agents and apparatuses for transduction |
| US11473059B2 (en) | 2015-10-22 | 2022-10-18 | Lucas Bio Co. Ltd. | Method for enrichment and expansion of virus antigen-specific T cells |
| CN108289913A (zh) | 2015-10-30 | 2018-07-17 | 儿童国家医疗中心 | 从未致敏t细胞群体产生hpv抗原特异性t细胞 |
| US20190032013A1 (en) * | 2016-01-29 | 2019-01-31 | Tract Therapeutics, Inc. | Immune cell selection, expansion, and use |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| MA45595A (fr) | 2016-07-07 | 2019-05-15 | Iovance Biotherapeutics Inc | Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation |
| HUE066460T2 (hu) | 2016-10-26 | 2024-08-28 | Iovance Biotherapeutics Inc | A kriokonzervált tumor infiltráló limfociták restimulációja |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| KR102618948B1 (ko) | 2016-11-17 | 2023-12-27 | 이오반스 바이오테라퓨틱스, 인크. | 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법 |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US10821134B2 (en) | 2017-05-17 | 2020-11-03 | Board Of Regents, The University Of Texas System | BK virus specific T cells |
| MY206158A (en) | 2017-05-24 | 2024-12-02 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| AR112072A1 (es) | 2017-06-05 | 2019-09-18 | Iovance Biotherapeutics Inc | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| EP3737743A1 (en) | 2018-01-08 | 2020-11-18 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| WO2019210131A1 (en) | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) * | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| FR3082524B1 (fr) * | 2018-06-18 | 2022-03-25 | Univ Paris Sud | Methode de stratification du risque de nephropathie a bk-virus apres transplantation renale |
| MY210603A (en) | 2018-11-05 | 2025-10-01 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| US12611427B2 (en) | 2018-11-05 | 2026-04-28 | Iovance Biotherapeutics, Inc. | Treatment of NSCLC patients refractory for anti-PD-1 antibody |
| SG11202104611YA (en) | 2018-11-08 | 2021-06-29 | Neximmune Inc | T cell compositions with improved phenotypic properties |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| US10772914B1 (en) | 2019-04-18 | 2020-09-15 | Baylor College Of Medicine | EBV-specific immune cells |
| US12516291B2 (en) | 2019-12-11 | 2026-01-06 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same |
| CN115997008A (zh) | 2020-04-22 | 2023-04-21 | 艾欧凡斯生物治疗公司 | 协调用于患者特异性免疫疗法的细胞的制造的系统和方法 |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
| US11781100B2 (en) | 2020-12-03 | 2023-10-10 | Applied Materials, Inc. | All-in-one bioreactor for therapeutic cells manufacturing |
| WO2022180452A1 (en) * | 2021-02-25 | 2022-09-01 | Senthilkumar NATESAN | Method of generating t cells from peripheral blood precursors and uses thereof |
| JP2024512029A (ja) | 2021-03-25 | 2024-03-18 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用 |
| JP2024526837A (ja) | 2021-07-18 | 2024-07-19 | ガミダ セル リミテッド | 治療用ｎｋ細胞集団 |
| CN119317705A (zh) * | 2022-02-15 | 2025-01-14 | 马克治疗公司 | 用于抗原特异性t细胞扩增的组合物和方法 |
| JP2025512401A (ja) | 2022-04-15 | 2025-04-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス |
| EP4587549A2 (en) * | 2022-09-15 | 2025-07-23 | Life Technologies Corporation | Bioreactors operable in static and dynamic modes and methods of use |
| WO2024145700A1 (pt) * | 2023-01-02 | 2024-07-11 | Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein | Método de expansão de linfócitos vírus-específicos, composição e uso de uma composição |
| US20250144143A1 (en) * | 2023-11-06 | 2025-05-08 | Immunitybio, Inc. | Virally Educated T cells |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641628A (en) | 1989-11-13 | 1997-06-24 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
| AU4678993A (en) | 1992-07-16 | 1994-02-14 | Board Of Trustees Of The Leland Stanford Junior University | Methods for using dendritic cells to activate t cells |
| US6821778B1 (en) | 1993-12-01 | 2004-11-23 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells |
| ES2153895T3 (es) | 1994-03-08 | 2001-03-16 | Dana Farber Cancer Inst Inc | Metodos para modular la insensibilidad de celulas t. |
| AUPM446594A0 (en) | 1994-03-16 | 1994-04-14 | Csl Limited | Cytotoxic t-cell epitopes identified within epstein-barr virus |
| WO1995027722A1 (en) | 1994-04-06 | 1995-10-19 | Immunex Corporation | Interleukin-15 |
| WO1995031208A1 (en) | 1994-05-16 | 1995-11-23 | Boehringer Mannheim Gmbh | Method of immunomodulation by means of adoptive transfer of antigen-specific cytotoxic t-cells |
| US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| DK0747481T3 (da) | 1995-06-06 | 2002-04-08 | Organon Teknika Bv | Epstein-Barr-viruspeptider og antistoffer mod disse peptider |
| FR2745185B1 (fr) | 1996-02-28 | 1998-05-15 | Sanofi Sa | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
| US6703024B2 (en) | 1996-05-24 | 2004-03-09 | The Council Of The Queensland Institute Of Medical Research | EBV CTL epitopes |
| US5962318A (en) | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
| CA2278189A1 (en) | 1997-01-31 | 1998-08-06 | Epimmune, Inc. | Peptides and peptide-loaded antigen presenting cells for the activation of ctl |
| AU7256498A (en) | 1997-04-25 | 1998-11-24 | Wistar Institute Of Anatomy And Biology, The | Cytolytic t-cell clones against colorectal carcinoma and methods of use thereof |
| US7951383B2 (en) | 1997-05-23 | 2011-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated parainfluenza virus (PIV) vaccines |
| AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| DE69840739D1 (de) | 1997-10-27 | 2009-05-28 | Merix Bioscience Inc | Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen |
| US20020155108A1 (en) | 1998-05-04 | 2002-10-24 | Biocrystal, Ltd. | Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells |
| US6828147B1 (en) | 1999-02-24 | 2004-12-07 | The Wistar Institute Of Anatomy And Biology | Method of modifying cytotoxic cells and uses thereof |
| WO2000050569A1 (en) | 1999-02-24 | 2000-08-31 | The Wistar Institute Of Anatomy And Biology | Method of modifying cytotoxic cells and uses thereof |
| US7005131B1 (en) | 1999-08-13 | 2006-02-28 | The Rockefeller University | Protective antigen of Epstein Barr Virus |
| US20150037297A1 (en) | 1999-08-30 | 2015-02-05 | David S Terman | Sickled Erythrocytes and Progenitors Target Cytotoxics to Tumors |
| DE60042606D1 (de) | 1999-11-24 | 2009-09-03 | Ernest G Hope | Anti-angiogener zellulärer wirkstoff zur krebsbehanldung |
| DE10009341A1 (de) | 2000-02-22 | 2001-09-06 | Florian Kern | Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten |
| US20020155127A1 (en) | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
| JP5184732B2 (ja) | 2000-06-19 | 2013-04-17 | ベス イスラエル デアコネス メディカル センター | Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法 |
| ES2292619T3 (es) | 2000-09-15 | 2008-03-16 | Ortho-Mcneil Pharmaceutical, Inc. | Composiciones y metodos para inducir respuestas citologicas especificas de la celula t. |
| EP1229043A1 (en) | 2001-01-30 | 2002-08-07 | Cyto-Barr B.V. | Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith |
| GB0107628D0 (en) | 2001-03-27 | 2001-05-16 | Avidex Ltd | Substances |
| US20040022761A1 (en) | 2001-05-11 | 2004-02-05 | Banchereau Jacques F | Compositions and methods for producing antigen-presenting cells |
| US7811816B2 (en) | 2001-05-15 | 2010-10-12 | Ortho-Mcneil Pharmaeutical, Inc. | Isolated CD8 +T lymphocytes specifically cytotoxic for a disease causing target cell |
| UA75429C2 (en) | 2001-09-28 | 2006-04-17 | Mowing blade | |
| EP1444330A1 (en) | 2001-11-07 | 2004-08-11 | Kirin Beer Kabushiki Kaisha | Expansion of t cells in vitro and expanded t cell populations |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| US7771998B2 (en) | 2001-11-29 | 2010-08-10 | Dandrit Biotech A/S | Pharmaceutical composition for inducing an immune response in a human or animal |
| US20040096457A1 (en) | 2001-12-11 | 2004-05-20 | Huber Brigitte T | Treatment and prevention of ebv infection and ebv-associated disorders |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| US20070048329A1 (en) | 2002-11-07 | 2007-03-01 | Rajiv Khanna | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| AU2002953238A0 (en) | 2002-12-09 | 2003-01-02 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | In vitro immunization |
| IL158140A0 (en) | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
| CN101120083B (zh) * | 2003-10-08 | 2013-03-27 | 威尔森沃尔夫制造公司 | 利用透气性材料进行细胞培养的方法及装置 |
| US20050221481A1 (en) | 2004-03-30 | 2005-10-06 | Istituto Superiore Di Sanita' | Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2 |
| US7785806B2 (en) | 2004-04-28 | 2010-08-31 | Vaxdesign Corporation | Method for determining the immunogenicity of an antigen |
| WO2005118788A2 (en) | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| US7785875B2 (en) | 2004-07-03 | 2010-08-31 | Mogam Biotechnology Research Institute | Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same |
| US20060045883A1 (en) | 2004-08-26 | 2006-03-02 | Jeffrey Molldrem | Anti-cancer vaccines |
| JP4731867B2 (ja) | 2004-10-01 | 2011-07-27 | 国立大学法人三重大学 | Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法 |
| WO2006099448A2 (en) | 2005-03-14 | 2006-09-21 | University Of Iowa Research Foundation | Accelerated cd8+ t-cell memory after dendritic cell vaccination |
| EP1712615A1 (en) | 2005-04-15 | 2006-10-18 | Txcell | In vitro production of a cell population using feeder cells |
| ATE451618T1 (de) | 2005-04-20 | 2009-12-15 | Hoffmann La Roche | Verfahren zur identifizierung von epitopen in zusammenhang mit immunogenität bei biopharmazeutika |
| AU2006247802A1 (en) | 2005-05-11 | 2006-11-23 | The Trustees Of The University Of Pennsylvania | Methods for the rapid expansion of antigen specific T-cells |
| US20070003531A1 (en) | 2005-06-30 | 2007-01-04 | University Of Connecticut | Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes |
| US20100035282A1 (en) | 2005-08-03 | 2010-02-11 | Maria Chiara Bonini | Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes |
| JP4824389B2 (ja) | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途 |
| AU2006338570B2 (en) | 2005-11-18 | 2013-07-11 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
| PL1989544T3 (pl) | 2006-03-02 | 2012-01-31 | Antitope Ltd | Testy na komórkach T |
| WO2007121276A2 (en) | 2006-04-12 | 2007-10-25 | Biocept, Inc. | Enrichment of circulating fetal dna |
| WO2008025992A2 (en) | 2006-09-01 | 2008-03-06 | Cambridge Enterprise Limited | Methods of expanding non-effector cd8 t-cell populations |
| US7846446B2 (en) | 2006-11-22 | 2010-12-07 | Board Of Trustees Of The University Of Arkansas | Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer |
| US20080176318A1 (en) | 2006-12-07 | 2008-07-24 | Wilson John R | Highly efficient devices and methods for culturing cells |
| PL2117571T3 (pl) | 2006-12-08 | 2017-08-31 | Monopar Therapeutics Inc. | Epitop receptora aktywatora plazminogenu typu urokinazy |
| DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
| CA2700618A1 (en) | 2007-09-27 | 2009-04-02 | The Board Of Trustees Of The University Of Arkansas | Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor |
| EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| EP2207875A1 (en) | 2007-10-24 | 2010-07-21 | Anne Letsch | Antigen-specific t-cell preparations from bone marrow |
| JP2011502484A (ja) | 2007-11-01 | 2011-01-27 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用 |
| EP2065462A1 (en) | 2007-11-27 | 2009-06-03 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens |
| CA2736851A1 (en) | 2008-09-11 | 2010-03-18 | Lung-Ji Chang | System and method for producing t cells |
| CN101824400B (zh) | 2009-03-05 | 2012-08-08 | 中国科学院微生物研究所 | 一种放大增殖抗原特异性t细胞的方法 |
| CN102625832A (zh) | 2009-08-24 | 2012-08-01 | 贝勒医学院 | 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系 |
| WO2011024482A1 (ja) | 2009-08-29 | 2011-03-03 | 株式会社バイオメッドコア | 抗原特異的ｔ細胞誘導能測定法 |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
| EP2510086A4 (en) | 2009-12-08 | 2013-05-22 | Wolf Wilson Mfg Corp | IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| US9114100B2 (en) | 2010-05-17 | 2015-08-25 | Duke University | Methods of treatment using ex vivo expansion of cord blood T cells |
| US20130129713A1 (en) | 2010-08-04 | 2013-05-23 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Method of antigen loading for immunotherapy |
| WO2012054792A2 (en) | 2010-10-22 | 2012-04-26 | Virginia Commonwealth University | Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells |
| EP2453243A1 (en) | 2010-11-11 | 2012-05-16 | Cosmo S.p.A. | Method for the diagnosis and/or follow up of the evolution of a tumor |
| US20130045491A1 (en) | 2011-07-19 | 2013-02-21 | Derya Unutmaz | Methods for activating t cells |
| WO2013035099A1 (en) | 2011-09-08 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| KR101749195B1 (ko) | 2011-12-12 | 2017-06-20 | 셀 메디카 리미티드 | T 세포들을 증식시키는 방법 |
| ES2748652T3 (es) | 2012-02-09 | 2020-03-17 | Baylor College Medicine | Mezclas pep para generar CTL multivíricos con amplia especificidad |
| US20130217122A1 (en) | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
| CN104428411B (zh) | 2012-05-08 | 2018-11-23 | 健康科学西部大学 | 用于cd4+t细胞群之抗原特异性扩增的标准化离体平台 |
| EP3071686B1 (en) | 2013-11-22 | 2020-07-22 | Cellectis SA | Method for generating batches of allogeneic t-cells with averaged potency |
| JP5870082B2 (ja) | 2013-12-19 | 2016-02-24 | 住友ゴム工業株式会社 | 重荷重用タイヤ |
| EP3097416A2 (en) | 2014-01-21 | 2016-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for testing t cell priming efficacy in a subject |
| WO2016073595A1 (en) | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
| AU2015343239B2 (en) | 2014-11-05 | 2021-06-03 | Memorial Sloan Kettering Cancer Center | Methods of selecting T cell line and donor thereof for adoptive cellular therapy |
| US20180072990A1 (en) | 2015-03-20 | 2018-03-15 | Children's National Medical Center | Generating virus or other antigen-specific t cells from a naïve t cell population |
| WO2016209816A1 (en) | 2015-06-26 | 2016-12-29 | Memorial Sloan Kettering Cancer Center | Methods of treating cmv retinitis by t cell therapy |
| EP3350600A4 (en) | 2015-09-18 | 2019-04-17 | Baylor College of Medicine | DISTINCTION OF AN IMMUNOGENIC ANTIGEN OF A PATHOGEN AND CORRELATION WITH CLINICAL EFFECTIVENESS |
| IL262989B2 (en) | 2016-05-25 | 2025-08-01 | Council Queensland Inst Medical Res | Methods for treating autoimmune disease using allogeneic T cells |
| JP7002769B2 (ja) | 2016-09-16 | 2022-02-04 | ベイラー カレッジ オブ メディスン | ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム |
| EP3516043A1 (en) | 2016-09-26 | 2019-07-31 | Tessa Therapeutics Pte. Ltd. | T cell expansion method |
| EP3641807A4 (en) | 2017-06-22 | 2021-04-21 | The Westmead Institute For Medical Research | Adoptive t cell therapy 2 |
| US11646103B2 (en) | 2017-09-06 | 2023-05-09 | Nant Holdings Ip, Llc | HLA tissue matching and methods therefor |
| JP7656331B2 (ja) | 2019-03-25 | 2025-04-03 | ベイラー カレッジ オブ メディスン | 複数の呼吸器ウイルス抗原に特異的なｔ細胞及びその作製方法及び治療での使用方法 |
| AR118859A1 (es) | 2019-05-08 | 2021-11-03 | Neon Therapeutics Inc | Composiciones y métodos de fabricación de células t |
| EP3986457A1 (en) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines |
| US20220257654A1 (en) | 2019-07-23 | 2022-08-18 | Baylor College Of Medicine | Antigen-specific t cell banks and methods of making and using the same therapeutically |
| MX2022001322A (es) | 2019-07-29 | 2022-05-24 | Baylor College Medicine | Bancos de células t específicas de antígeno y métodos para fabricar y usar los mismos terapéuticamente. |
| AU2020333654A1 (en) | 2019-08-16 | 2022-03-17 | Baylor College Of Medicine | Third party virus-specific T cell compositions, and methods of making and using the same in anti-viral prophylaxis |
| EP4081226A4 (en) | 2019-12-23 | 2024-03-27 | Baylor College of Medicine | T CELL PERFORMANCE ASSAY AS A PROGNOSIS FACTOR FOR CLINICAL OUTCOME |
| JP2023518792A (ja) | 2020-03-20 | 2023-05-08 | ベイラー カレッジ オブ メディスン | ＳＡＲＳ－ＣｏＶ２特異的Ｔ細胞組成物ならびにコロナウイルスおよび他の呼吸器系ウイルス感染症の処置および予防におけるそれらの使用 |
| EP3974029A1 (en) | 2020-09-25 | 2022-03-30 | Universidad Autónoma de Madrid | Memory t cells as adoptive cell therapy for viral infections |
| CN119317705A (zh) | 2022-02-15 | 2025-01-14 | 马克治疗公司 | 用于抗原特异性t细胞扩增的组合物和方法 |
-
2011
- 2011-12-12 GB GBGB1121308.9A patent/GB201121308D0/en not_active Ceased
-
2012
- 2012-12-12 HK HK15103777.6A patent/HK1203219A1/xx unknown
- 2012-12-12 WO PCT/GB2012/053113 patent/WO2013088147A1/en not_active Ceased
- 2012-12-12 EP EP12816092.6A patent/EP2791323A2/en not_active Withdrawn
- 2012-12-12 WO PCT/GB2012/053114 patent/WO2013088148A2/en not_active Ceased
- 2012-12-12 JP JP2014546634A patent/JP2015505852A/ja active Pending
- 2012-12-12 US US14/364,626 patent/US20140341951A1/en not_active Abandoned
- 2012-12-12 US US14/364,621 patent/US20150044258A1/en not_active Abandoned
- 2012-12-12 AU AU2012351842A patent/AU2012351842B2/en active Active
- 2012-12-12 EP EP12815750.0A patent/EP2791163B2/en active Active
- 2012-12-12 ES ES12815750T patent/ES2626492T5/es active Active
- 2012-12-12 AU AU2012351843A patent/AU2012351843B2/en not_active Ceased
- 2012-12-12 JP JP2014546633A patent/JP6203745B2/ja active Active
-
2015
- 2015-12-28 US US14/981,440 patent/US20160184361A1/en not_active Abandoned
-
2017
- 2017-07-06 JP JP2017132663A patent/JP6657145B2/ja active Active
-
2018
- 2018-06-22 US US16/016,305 patent/US11963979B2/en active Active
-
2019
- 2019-11-08 JP JP2019203285A patent/JP2020022505A/ja not_active Withdrawn
-
2022
- 2022-01-27 US US17/586,698 patent/US20220152111A1/en active Pending
- 2022-04-13 JP JP2022066435A patent/JP2022089916A/ja active Pending
-
2023
- 2023-10-17 JP JP2023179166A patent/JP2023174861A/ja not_active Withdrawn
-
2025
- 2025-10-17 US US19/361,743 patent/US20260042987A1/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| BLOOD, Vol. 116, No. 21, 19 November 2010 p546. * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2791163B1 (en) | 2017-03-01 |
| AU2012351842A1 (en) | 2014-08-07 |
| US20260042987A1 (en) | 2026-02-12 |
| HK1203219A1 (en) | 2015-10-23 |
| JP2015505852A (ja) | 2015-02-26 |
| WO2013088147A1 (en) | 2013-06-20 |
| US20150044258A1 (en) | 2015-02-12 |
| EP2791163A1 (en) | 2014-10-22 |
| HK1203210A1 (en) | 2015-10-23 |
| JP6203745B2 (ja) | 2017-09-27 |
| WO2013088148A3 (en) | 2013-09-06 |
| WO2013088148A2 (en) | 2013-06-20 |
| US20140341951A1 (en) | 2014-11-20 |
| JP2015501653A (ja) | 2015-01-19 |
| JP2017169594A (ja) | 2017-09-28 |
| ES2626492T5 (en) | 2025-04-15 |
| AU2012351843A1 (en) | 2014-07-31 |
| US20190134092A1 (en) | 2019-05-09 |
| JP2022089916A (ja) | 2022-06-16 |
| EP2791323A2 (en) | 2014-10-22 |
| GB201121308D0 (en) | 2012-01-25 |
| ES2626492T8 (es) | 2018-07-13 |
| JP6657145B2 (ja) | 2020-03-04 |
| AU2012351842B2 (en) | 2016-05-26 |
| US20160184361A1 (en) | 2016-06-30 |
| US11963979B2 (en) | 2024-04-23 |
| EP2791163B2 (en) | 2024-11-27 |
| JP2020022505A (ja) | 2020-02-13 |
| US20220152111A1 (en) | 2022-05-19 |
| ES2626492T3 (es) | 2017-07-25 |
| JP2023174861A (ja) | 2023-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012351843B2 (en) | Method of treatment employing therapeutic T cell product from mobilised donors | |
| US10000736B2 (en) | Method for priming of T cells | |
| JP6081483B2 (ja) | Ｔ細胞を増殖させるプロセス | |
| Derré et al. | BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination | |
| KR102395528B1 (ko) | 입양 세포 치료를 위한 t 세포주 및 이의 도너를 선택하는 방법 | |
| Sun et al. | Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a production assistant for cell therapy (PACT) translational application | |
| Gary et al. | Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts | |
| Horlock et al. | Manufacture of GMP-compliant functional adenovirus-specific T-cell therapy for treatment of post-transplant infectious complications | |
| US20020064874A1 (en) | Method for obtaining specific T-lymphocytes, and for identifying unknown epitopes | |
| Meckiff | Evolution of the human CD4+ T cell response to Epstein-Barr virus infection-analysis of systemic and local immune responses | |
| Lindeman | Evaluation of a Novel Method Used to Generate CMV-Specific Cytotoxic T Lymphocytes | |
| D’Orsogna et al. | Stimulation of human viral specific cytolytic effector function using allogeneic cell therapy | |
| HK1203210B (en) | Process for t cell expansion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |